Author

Anandkumar Dubey

Observed name: Dubey, Anandkumar

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Bristol-Myers Squibb (United States), University of Pennsylvania

ORCID: 0009-0009-4789-0489

Observed ORCID: 0009-0009-4789-0489

OpenAlex ID: A5108317277

Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten

2024 · Nosheen Reza, Anandkumar Dubey, et al. · JACC Heart Failure · 15

Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population

2025 · Nipun Atreja, Anandkumar Dubey, et al. · Advances in Therapy · 7

Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks

2025 · Nosheen Reza, Anandkumar Dubey, et al. · Journal of Clinical Medicine · 5

Associations between procedural volume, costs, and outcomes of septal reduction therapies for obstructive hypertrophic cardiomyopathy in US hospitals

2025 · Ervant J. Maksabedian Hernandez, Shanthi Krishnaswami, et al. · Journal of Medical Economics · 3

Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real‐World Study in Patients With Nonvalvular Atrial Fibrillation

2026 · Gregory Y. H. Lip, Dong Cheng, et al. · Journal of the American Heart Association · 2

26-a-11566-acc Real-world Evidence From the Marvel-hcm Multicenter Study of Mavacamten — a Sex-based Analysis of Baseline Characteristics and Cardiac Structural and Functional Changes

2026 · Matthew W. Martinez, Matthew Thomas Wheeler, et al. · Journal of the American College of Cardiology · 1

Demographic and Socio-Economic Disparities in the Outcomes Among Patients with NVAF Treated with Oral Anticoagulants: A Real-World Evaluation of Medicare Beneficiaries

2025 · Nipun Atreja, Anandkumar Dubey, et al. · Journal of Clinical Medicine · 1

Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy

2026 · Anjali T. Owens, Patricia Schuler, et al. · Journal of the American Heart Association

Association between increased Patients' out-of-pocket costs for apixaban and oral anticoagulant discontinuation in high-risk patients with atrial fibrillation - a retrospective Medicare claims study

2025 · Dominick Latremouille-Viau, Aolin Wang, et al. · Blood

Impact of increased patient out-of-pocket costs on oral anticoagulant discontinuation among Medicare beneficiaries with atrial fibrillation treated with apixaban

2025 · Dominick Latremouille-Viau, Aolin Wang, et al. · Current Medical Research and Opinion

Evaluation of the treatment patterns among commercially insured patients with nonvalvular atrial fibrillation prescribed an oral anticoagulant by race/ethnicity

2025 · Michelle Zhang, Risho Singh, et al. · Journal of Comparative Effectiveness Research

HPR109 Impact of Increased Patients' Out-of-Pocket Costs on Oral Anticoagulant Discontinuation among Medicare Beneficiaries with Atrial Fibrillation Treated with Apixaban

2025 · Dominick Latremouille-Viau, Aolin Wang, et al. · Value in Health

Real-world Long-term Effectiveness of Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: a Multicenter Observational Study (MARVEL-HCM)

2025 · Patricia Schuler, Theodore Abraham, et al.

Real World Experience and 24-week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten in the Us

2024 · Nosheen Reza, Anandkumar Dubey, et al. · Journal of the American College of Cardiology

Works count: 16

Citation count: 34

H-index: 3

I10-index: 1